Volume 9, Issue 11

Women With CF: Clinical Considerations

In this issue:

Studies have shown that adolescent and young adult women with cystic fibrosis often turn to their CF care team for answers to their questions about their sexual and reproductive health. But how prepared are CF clinicians to initiate conversations? Do they have the most current data about pregnancy decisions for women taking CFTR modulators? When should modulator therapy be stopped? When is it safe to continue?  

In this eCysticFibrosis Review podcast, Dr. Traci Kazmerski from UPMC Children's Hospital of Pittsburgh and Dr. Natalie West from Johns Hopkins University take us into the clinic to address these important questions. 

Learning objectives:

  • Describe strategies to initiate discussions related to sexual and reproductive health concerns with women with CF. 
  • Explain the potential risks and benefits of continuing or discontinuing CFTR modulator therapy in pregnancy.

Authors:

Traci Kazmerski, MD, MS
Traci Kazmerski, MD, MS

Assistant Professor of Pediatrics  
Division of Adolescent and Young Adult Medicine 
UPMC Children's Hospital of Pittsburgh 
Pittsburgh, PA

Natalie E. West, MD, MHS
Natalie E. West, MD, MHS

Assistant Professor of Medicine 
Associate Program Director, Pulmonary and Critical Care Fellowship 
Pulmonary and Critical Care Medicine 
Johns Hopkins University 
Baltimore, MD

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD, MBA

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Donna Peeler, RN

Clinical Nurse 
Pediatric Clinic Coordinator 
Johns Hopkins Cystic Fibrosis Center 
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: November 28, 2020
Expiration date: November 27, 2022